Project Details
Description
A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF COMP360 IN PARTICIPANTS WITH TREATMENT-RESISTANT DEPRESSION
| Status | Active |
|---|---|
| Effective start/end date | 4/4/23 → 4/30/28 |
Funding
- COMPASS PATHFINDER HOLDINGS LIMITED
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.